Notably, in patients with brain metastases, the hazard ratio (HR) for disease progression was 0.639, indicating a meaningful reduction in the risk of progression and reinforcing the therapeutic potential of this regimen for HER2+ breast cancer patients with brain metastases [100]. This evidence concerns the gene ERBB2 and breast cancer.